Estriol is the weakest of the three main estrogens your body produces, but its blood levels undergo one of the most dramatic shifts in all of human physiology. Outside of pregnancy, circulating estriol hovers in the single-digit picograms per milliliter range. During the third trimester, levels climb to concentrations thousands of times higher, driven almost entirely by the fetal-placental unit. That enormous swing makes estriol a uniquely useful marker in prenatal screening, a signal of fetal wellbeing, and an increasingly studied therapeutic molecule for conditions ranging from recurrent urinary tract infections to multiple sclerosis.
Estriol Levels in Non-Pregnant Women
In women who are not pregnant, estriol circulates at very low concentrations compared to estradiol and estrone. During the early follicular phase of the menstrual cycle (roughly days 5 through 7), average plasma estriol sits around 7 to 8 pg/mL. In the luteal phase (days 20 through 22), that rises modestly to about 11 pg/mL.1PubMed. Estriol concentrations in plasma of normal, non-pregnant women Independent measurements in a separate group of young women found nearly identical values, with follicular-phase estriol averaging about 7 pg/mL and luteal-phase estriol around 11 pg/mL.2The Journal of Clinical Endocrinology & Metabolism. The Metabolic Clearance and Blood Production Rates of Estriol in Normal, Non-Pregnant Women
After menopause, estriol drops further. Postmenopausal women average about 6 pg/mL, which is lower than the luteal-phase peak but not dramatically different from the follicular-phase baseline.3PubMed. Estriol concentrations in plasma of normal, non-pregnant women The practical point is that outside of pregnancy, estriol is a minor player. It is present, it fluctuates modestly with the cycle, and it fades somewhat after menopause, but it never reaches the concentrations that make it clinically important in the way it becomes during gestation.
The Dramatic Rise During Pregnancy
Pregnancy transforms estriol from a trace hormone into the dominant estrogen in your bloodstream. The reason is that estriol production depends on a collaboration between the fetal adrenal glands, the fetal liver, and the placenta. The fetus makes a precursor (a steroid called DHEA-S), which is then hydroxylated by the fetal liver and finally converted into estriol by the placenta. Without a functioning fetus and placenta working together, the massive amounts of estriol seen in late pregnancy simply cannot be produced.
Serial blood measurements in normal pregnancies show that unconjugated estriol begins to rise around the tenth week of pregnancy, and after the twelfth week, that increase becomes steeper than the rises in estradiol or estrone.4The Journal of Clinical Endocrinology & Metabolism. Plasma Levels of Unconjugated Estrone, Estradiol and Estriol and of HCS Throughout Pregnancy in Normal Women Between about 18 and 30 weeks, all three estrogens climb in a roughly parallel fashion. Then, after 30 weeks, estriol pulls away again, accelerating faster than its relatives all the way to term.
The trajectory is not perfectly smooth. Third-trimester data reveal a brief plateau in estriol between roughly 31 and 35 weeks, followed by a steep surge around 36 weeks that snaps values back onto the overall upward trend line.5PubMed. Serum unconjugated estriol levels in the third trimester and their relationship to gestational age Clinicians who interpret single estriol values need to be aware of this pause so they do not mistake a normal 32-week plateau for a worrying decline.
Estriol in Prenatal Screening
Unconjugated estriol (abbreviated uE3) is one of the four analytes measured in the second-trimester “quad screen,” a blood test typically drawn between 15 and 20 weeks of pregnancy. The other three markers are alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), and inhibin A. Together, these four substances help estimate the probability of certain chromosomal abnormalities, especially Down syndrome.
In pregnancies affected by Down syndrome, uE3 tends to be lower than expected. In one large population-based study of over 21,000 pregnancies, the median uE3 in affected cases was about 0.77 multiples of the median (MoM), meaning roughly three-quarters of the normal expected value.6PubMed. Second-trimester maternal serum quadruple test for Down syndrome screening: a Taiwanese population-based study Adding uE3 and inhibin A to the older “double test” (AFP and hCG alone) improved the detection rate from about 63% to 72% at the same false-positive cutoff.7PubMed. Second-trimester Down’s syndrome serum screening: double, triple or quadruple marker testing? That improvement is meaningful but modest, which is why estriol always works as part of a panel rather than as a standalone test. No single marker is sensitive enough on its own.
More recently, researchers have found that the same quad-screen biomarkers carry information beyond chromosomal screening. Low uE3 values, alongside elevated AFP and hCG, have been linked to higher odds of preterm birth. In a large population-based study, lower uE3 was inversely associated with both overall preterm birth and very early preterm birth, with a stronger effect size for the earliest deliveries.8PubMed Central. Second trimester quad test for fetal down syndrome screening as a predictor of spontaneous preterm birth in a developing country: a population-based study This does not mean the quad screen is used clinically to predict preterm labor, but it suggests that the placental function reflected by these markers has broader implications than screening for trisomies alone.
When Very Low Estriol Points to Metabolic Disorders
Unusually low uE3 on a screening test sometimes signals not a chromosomal problem but a metabolic one in the fetus. Two conditions stand out. The first is Smith-Lemli-Opitz syndrome (SLOS), a rare disorder of cholesterol synthesis. Because cholesterol is a building block for all steroid hormones, a fetus with SLOS cannot produce the precursors that eventually become estriol. In one study, two cases of SLOS were identified through markedly low uE3, and neither infant survived the newborn period.9PubMed. Maternal serum unconjugated estriol as a predictor for Smith-Lemli-Opitz syndrome and other fetal conditions
The second and more common condition flagged by low uE3 is steroid sulfatase deficiency (also known as X-linked ichthyosis), a skin disorder that almost exclusively affects boys. In this case, the fetus lacks the enzyme needed to cleave the sulfate group off the estriol precursor, so the precursor never reaches the placenta for conversion.10Genetics in Medicine. Low maternal serum estriol as a marker for steroid sulfatase deficiency A very low or undetectable uE3 in the quad screen, especially in a pregnancy carrying a male fetus, should prompt investigation for this condition. Other rare causes of low estriol include fetal adrenal hypoplasia and maternal use of high-dose corticosteroids, which suppress fetal adrenal function.
Salivary Estriol and Preterm Birth
Because estriol can be measured in saliva as well as blood, researchers have explored whether salivary estriol might serve as a convenient, non-invasive predictor of preterm labor. The logic is straightforward: estriol rises before labor begins, so an unexpectedly early spike could be a warning sign. A study comparing women in active preterm labor with women of similar gestational age who were not in labor found that salivary estriol levels were about five times higher in the preterm labor group.11Indonesian Journal of Obstetrics and Gynecology. The Salivary Estriol Level was Higher in Preterm Delivery Compared to that in Preterm Pregnancy
There is also evidence that medications taken during pregnancy can alter salivary estriol. Women with a history of major depression who were treated with antidepressants during pregnancy had significantly higher mean estriol levels in the second half of pregnancy compared to women with the same psychiatric history who were not on medication, and compared to healthy controls.12PubMed Central. Saliva estriol levels in women with and without prenatal antidepressant treatment The clinical meaning of this elevation remains unclear, but it complicates any simple interpretation of salivary estriol as a preterm birth predictor in women taking antidepressants.
Vaginal Estriol for Postmenopausal Health
After menopause, the drop in all estrogens leads to thinning and drying of the vaginal and urethral tissues, a cluster of symptoms sometimes called genitourinary syndrome of menopause. Because estriol is the weakest estrogen, it has long been used locally (as a cream or pessary) to restore tissue health without producing the systemic estrogen exposure associated with estradiol pills or patches.
A recent randomized, placebo-controlled trial tested an ultra-low-dose vaginal estriol gel for preventing urinary tract infections in postmenopausal women. The estriol group had a roughly 26% lower rate of new UTIs compared to placebo, and vaginal pH improved at every follow-up visit.13PubMed. Efficacy and safety of an ultra-low-dose 0.005 % estriol vaginal gel in the prevention of urinary tract infections in postmenopausal women with genitourinary syndrome of menopause The pH change matters because a more acidic vaginal environment supports the growth of lactobacilli, which help crowd out the bacteria responsible for UTIs.
A key concern with any estrogen therapy, even local, is whether it stimulates the uterine lining. The evidence on vaginal estriol at recommended doses is reassuring. A review covering all published post-baseline biopsies in women using intravaginal estriol found that every single biopsy (337 total) came back classified as atrophic, with no endometrial proliferation or hyperplasia.14PubMed. Review of the endometrial safety during intravaginal treatment with estriol A broader systematic review of low-dose vaginal estrogens, which included estriol formulations, similarly found no increased risk of endometrial hyperplasia or cancer, with rates matching those in the general population.15PubMed Central. Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review
There is an important distinction between vaginal and oral use, though. One review noted that while vaginal low-potency estrogen formulations like estriol did not appear to raise endometrial cancer risk, long-term oral use was a different story.16PubMed. Endometrial safety of hormone replacement therapy: review of literature The route of administration matters because oral estriol at higher doses may reach the uterine lining in quantities sufficient to stimulate growth, whereas vaginal estriol at low doses acts primarily on local tissue.
Estriol and Multiple Sclerosis
One of the more intriguing areas of estriol research has nothing to do with pregnancy or menopause. Women with relapsing-remitting multiple sclerosis (MS) frequently experience fewer relapses during pregnancy, particularly in the third trimester when estriol is at its peak. This clinical observation led researchers to test whether giving estriol as a drug could reproduce pregnancy’s protective effect on the immune system.
In a pilot trial, women with relapsing-remitting MS who took oral estriol at 8 mg per day showed significant decreases in gadolinium-enhancing brain lesions on MRI (a marker of active inflammation), along with reductions in immune markers associated with the type of inflammation that drives MS.17PubMed. Treatment of multiple sclerosis with the pregnancy hormone estriol When estriol was stopped, the lesions came back. When it was restarted, they decreased again. That on-off pattern strongly suggests the estriol itself was responsible.
Immunological work on these same patients showed that estriol pushed the immune system toward a pattern that dampens the type of inflammatory response thought to drive MS.18The Journal of Immunology. Immune Modulation in Multiple Sclerosis Patients Treated with the Pregnancy Hormone Estriol A larger phase 2 trial then combined estriol with glatiramer acetate (an existing MS drug) and compared this to glatiramer acetate plus placebo. The estriol group had a lower annualized relapse rate, though the difference did not quite reach conventional statistical significance.19The Lancet Neurology. Estriol combined with glatiramer acetate in women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled phase 2 trial The results were encouraging enough that estriol remains under study as an add-on MS therapy, but it is not an approved treatment for the disease.
Estriol, Bone Density, and Cardiovascular Research
Estriol has been studied in two other domains that interest postmenopausal women: bone loss and heart disease. In a small Japanese trial, postmenopausal and elderly women who took estriol for 10 months showed a significant average increase in lumbar spine bone mineral density, around 5.6% from baseline, while untreated controls lost bone density over the same period.20PubMed. Effect of estriol and bone mineral density of lumbar vertebrae in elderly and postmenopausal women The researchers noted that even the low-turnover bone typical of older women responded to estriol, which was somewhat unexpected. Still, this was a small study, and estriol has never been adopted into mainstream osteoporosis guidelines the way estradiol-based hormone therapy has.
On the cardiovascular side, animal research has shown that estriol treatment restored nitric oxide (NO) release in the aorta and increased levels of cyclic GMP, a signaling molecule involved in keeping blood vessels relaxed. In an animal model of atherosclerosis, estriol was effective at slowing plaque progression and stabilizing existing plaques, in some measures more so than estradiol.21PubMed. Estriol retards and stabilizes atherosclerosis through an NO-mediated system These findings remain preclinical. No large human trial has tested estriol specifically for cardiovascular protection.
The Breast Cancer Hypothesis
Among the most debated aspects of estriol is whether high pregnancy levels might protect against breast cancer. The idea has been around for decades: women with more pregnancies tend to have lower lifetime breast cancer risk, and estriol is the estrogen that climbs most dramatically during pregnancy. A prospective study that measured third-trimester estrogen levels and then followed women for years afterward found that a doubling of estriol was associated with about a 30% lower risk of later breast cancer. The ratio of estriol to estrone-plus-estradiol was even more protective, with a doubling of that ratio linked to roughly 40% lower risk.22PubMed Central. Third Trimester Estrogens and Maternal Breast Cancer: Prospective Evidence
This is an observational finding, not proof that taking estriol supplements would prevent cancer. Women with higher third-trimester estriol may differ from women with lower levels in ways that independently affect breast cancer risk. The hypothesis remains active in the research literature but far from settled. It does, however, feed into marketing claims by some compounded-hormone pharmacies, which brings us to a separate set of concerns.
Compounded “Bi-Est” and “Tri-Est” Formulations
Walk into certain integrative or anti-aging clinics and you will encounter compounded hormone preparations that combine estriol with estradiol (bi-est) or with both estradiol and estrone (tri-est). These are custom-mixed by compounding pharmacies and are not FDA-approved products. Proponents argue that including estriol makes the formulation safer or more “natural” because estriol is a weaker estrogen. The evidence base for these claims is thin. A case-series review concluded that there are insufficient data to support the efficacy or safety of compounded bioidentical hormone therapy and recommended the use of FDA-approved regimens instead.23PubMed. Risks and effectiveness of compounded bioidentical hormone therapy: a case series
The concern is not that estriol is dangerous in itself. As described above, low-dose vaginal estriol has a strong safety profile. The concern is that compounded products lack the standardized manufacturing, potency testing, and regulatory oversight of approved drugs. Dose accuracy can vary from batch to batch. And the theoretical rationale that estriol “blocks” stronger estrogens at the receptor has never been proven in clinical trials. If you are considering hormone therapy for menopausal symptoms, the most reliable data come from FDA-approved products, not from compounded blends marketed around the weaker-is-safer narrative.
Measuring Estriol Accurately
For a molecule that plays such an important role in prenatal screening, getting the measurement right matters. Most clinical labs measure unconjugated estriol using automated immunoassay platforms, which are fast and inexpensive. However, head-to-head comparisons against liquid chromatography–tandem mass spectrometry (LC-MS/MS), considered the gold-standard technique, have revealed concentration-dependent biases in the immunoassays.24PubMed. Measurement of unconjugated estriol in serum by liquid chromatography-tandem mass spectrometry and assessment of the accuracy of chemiluminescent immunoassays In plain terms, the routine tests tend to over- or under-read at certain estriol concentrations, which can affect screening risk calculations.
Researchers have developed LC-MS/MS reference methods that measure estriol without the chemical modification (derivatization) that older mass spectrometry protocols required, making the technique simpler and more practical for reference laboratories.25PubMed. Measurement of human serum unconjugated estriol without derivatization using liquid chromatography-tandem mass spectrometry candidate reference method and compared with two immunoassays For routine clinical practice, immunoassays remain standard and perform well enough for screening purposes. But labs and clinicians should be aware that the absolute number from one platform may not match the number from another, which is why screening algorithms are calibrated to each specific assay system rather than relying on universal cutoffs.
How Estriol Is Cleared From the Body
Estriol is metabolized primarily in the liver, where it is conjugated (attached to glucuronic acid or sulfate groups) to make it water-soluble for excretion in urine. A portion of orally administered estriol undergoes enterohepatic recycling: after being excreted into the gut via bile, gut bacteria can strip off the conjugate, allowing estriol to be reabsorbed. This recycling prolongs the hormone’s presence in the bloodstream after an oral dose, and the extent of recycling can be tracked by measuring the ratio of specific estriol metabolites in urine.26PubMed. Enterohepatic recycling of estrogen and its relevance with female fertility
This recycling loop has practical implications. Anything that disrupts gut bacteria, such as antibiotics, can reduce the reabsorption of estriol (and other estrogens), potentially lowering effective levels. Conversely, the recycling mechanism explains why even a “weak” estrogen like estriol, if taken orally at high enough doses, can accumulate enough to have systemic effects. This is one reason vaginal administration at low doses tends to be preferred for local symptoms: it delivers estriol where it is needed while minimizing the systemic exposure that oral dosing and enterohepatic recycling can produce.